Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

GHRP-6

Growth Hormone Releasing Peptide-6

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

GHRP-6 is a synthetic ghrelin-mimetic growth-hormone secretagogue and the first GHRP characterized by Bowers and colleagues in the early 1980s, whose acute GH, cortisol, ACTH, and appetite responses are well documented in small Phase I pharmacodynamic studies in humans. That human record is limited to short-term hormonal and orexigenic effects, with no controlled trials supporting body composition, recovery, or any clinical outcome, and no approved product exists, so an honest grade is anecdotal/mechanistic rather than outcome-supported. It reliably raises GH but is associated with strong appetite stimulation and modest, transient cortisol and prolactin increases, which is why cleaner secretagogues such as ipamorelin have largely replaced it.

FDA
Not Approved
WADA
Prohibited (S2)

Reference only. Not medical advice.

What can go wrong

Strong appetite stimulation via ghrelin pathway; transient cortisol and prolactin elevation; no approved product and sold as a research chemical not for human use; WADA prohibited under S2 in and out of competition.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about GHRP-6. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A first-generation growth-hormone secretagogue that stimulates GH release through the ghrelin receptor. Its major limitation is a strong appetite increase, which is why cleaner compounds like ipamorelin have largely replaced it.

The original GH secretagogue. Big appetite spike. Largely replaced by ipamorelin.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • GH stimulation
  • Appetite stimulation
  • Recovery

How it is supposed to work

GHRP-6 is a ghrelin mimic and a growth-hormone secretagogue. It switches on the ghrelin receptor in the pituitary, prompting robust, pulse-like bursts of the body’s own growth hormone, a different route than the GHRH hormone uses. But because it imitates ghrelin broadly, it does more than release growth hormone: it strongly stimulates appetite, speeds the emptying of the stomach, and at higher doses nudges up cortisol and prolactin. That breadth is its defining trait, for better and worse.

GHRP-6 is a synthetic hexapeptide, six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) including protease-resistant building blocks. It was synthesized by the endocrinologist Cyril Bowers in 1984 and is the founding member of the growth-hormone-releasing-peptide family. Its scientific importance is outsized: it is the compound that led researchers to discover the ghrelin receptor and, ultimately, the hormone ghrelin itself.

Type
GH secretagogue (hexapeptide)
Acts on
Ghrelin receptor
Effect
Pulsatile GH + appetite
Footprint
Cortisol, prolactin too
Approved
No
WADA
Prohibited (S2)

Releases Growth Hormone, And A Lot Else

GHRP-6’s growth-hormone-releasing effect is real and well-documented across decades, and its place in science history is genuine, it is the peptide that opened the door to ghrelin. But two honest points temper its use. First, it is the least selective of the growth-hormone-releasing peptides: alongside GH it triggers intense hunger, its signature effect, useful for the few who need it and counterproductive for most, while also speeding gastric emptying and raising cortisol and prolactin at higher doses. That broad hormonal footprint caps how high it can usefully be dosed, and it is precisely why the cleaner ipamorelin was engineered to replace it. Second, like every compound in this class, its GH release is proven while the downstream benefits people actually want, better body composition, recovery or longevity, are not validated by outcome trials. It is also banned in sport and unapproved.

Safety in detail

GHRP-6 has never been approved by any major regulator and is distributed as a research chemical labeled not for human consumption, so purity, dose, and long-term safety are not assured. Its most consistent effect beyond GH release is pronounced hunger through the same ghrelin/GHS-R1a orexigenic NPY and AgRP pathway that endogenous ghrelin uses.

  • Its signature effect is intense appetite stimulation within minutes, desirable for some users and counterproductive for most.
  • At higher doses it raises cortisol and prolactin, which caps effective dosing and can undermine the very gains users seek.
  • It accelerates gastric emptying, a ghrelin effect not shared by cleaner secretagogues.
  • Raising growth hormone carries the general cautions of GH elevation, including effects on insulin sensitivity.
  • There are no long-term human outcome data, it is banned in sport, and gray-market product carries the usual quality risks.

Children and teenagers

GHRP-6 is an unapproved growth-hormone secretagogue with appetite and cortisol effects, and has no place in minors. Genuine growth or GH disorders in children are treated with approved therapies under pediatric endocrinology, not gray-market secretagogues. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

GHRP-6 has no approved product; its market is gray, research-peptide vendors selling the hexapeptide cheaply and bodybuilding and anti-aging clinics offering it, often stacked with GHRH analogs. Its appetite-stimulating effect gives it a niche identity, but for most users the cleaner ipamorelin has taken over, leaving GHRP-6 as the historic original that newer, more selective options have largely displaced.

How we got here

GHRP-6 was one of the first synthetic growth hormone releasing peptides, developed from Cyril Bowers' structure-activity work on met-enkephalin analogues and characterized in 1984 as a hexapeptide that dose-dependently stimulates growth hormone release. It acts at the growth hormone secretagogue receptor, later identified as the ghrelin receptor, which makes it a functional ghrelin mimetic. Today it persists mainly as a research tool and a gray-market bodybuilding peptide.

Cyril Bowers synthesized GHRP-6 in 1984, the first synthetic growth-hormone-releasing peptide, and it became the foundation of the entire secretagogue field, leading to GHRP-2, hexarelin and others. Most importantly, it was the tool that led to the discovery of the ghrelin receptor and the hormone ghrelin. In the 1990s, ipamorelin was engineered as a selective successor that kept the GH release while shedding GHRP-6’s appetite, cortisol and prolactin effects. GHRP-6 persisted in bodybuilding gray markets, valued by some for its appetite effect, while its preclinical cardioprotective properties remained an area of research interest.

  1. 1984Bowers synthesizes GHRP-6, the first GH-releasing peptide.
  2. 1980s-1990sIt seeds the secretagogue field and becomes the tool that leads to ghrelin’s discovery.
  3. 1998Ipamorelin is introduced as a selective successor, defined against GHRP-6’s broad footprint.
  4. 2000s-2020sPersists in bodybuilding gray markets for GH release and appetite, often stacked with GHRH analogs.

The numbers behind the grade

Type
GH secretagogue (hexapeptide)
First GHRP
Yes (1984)
Appetite
Strongest of class
Extra effects
Cortisol, prolactin
Approved
No
WADA
Prohibited (S2)

The people taking it

The original, historic growth-hormone-releasing peptide, the one that led to ghrelin’s discovery, still used in bodybuilding and distinctive for intense appetite stimulation, but the least selective and largely superseded by cleaner secretagogues.

GHRP-6’s users are mostly bodybuilders and physique-focused users seeking GH release for muscle and recovery, some of whom specifically want its appetite boost for bulking, plus anti-aging and GH-optimization users and people stacking it with GHRH analogs. A smaller group values the appetite stimulation in recovery or low-appetite contexts. It is an enthusiast compound, increasingly chosen by those who specifically want what its broad footprint offers.

Used gray-market for GH release, muscle, recovery and appetite stimulation in bodybuilding and anti-aging, often stacked with GHRH analogs. Proven GH release but no outcome trials, banned in sport, unapproved.

Set against the alternatives

The defining comparison is to ipamorelin, the selective successor built to fix GHRP-6’s breadth: both hit the same receptor and release GH, but ipamorelin produces negligible appetite, cortisol or prolactin effects, making it the cleaner everyday tool. Against GHRP-2 and hexarelin, GHRP-6 sits in the middle, less GH peak and cortisol than GHRP-2 but the strongest appetite stimulation of the group. It is often stacked with a GHRH analog like the CJC-1295 family, which releases GH by a complementary mechanism for a synergistic pulse. And against actual growth hormone, GHRP-6 works with the body’s own pulsatile release rather than overriding it, but is correspondingly less powerful. Its strength is breadth and history; its weakness is that the breadth is mostly unwanted.

What we do not know

  • Whether its proven GH release translates into real body-composition, recovery or longevity benefits, which no outcome trial has shown.
  • Whether its intriguing preclinical cardioprotective signal holds up.
  • How best to manage its appetite, cortisol and prolactin footprint.
  • Why one would choose it over the cleaner, more selective ipamorelin.

What could change

Cardioprotection researchIts preclinical cardioprotective signal remains an intriguing research direction.Appetite nicheIts hunger-stimulating effect keeps it relevant for specific uses.Selective competitionCleaner secretagogues continue to displace it for general use.Persistent gray marketOngoing bodybuilding use despite the lack of outcome data.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available only as gray-market research material, which is not for human use and lacks outcome data. There is no legitimate route, and it is banned in sport. For those set on a GH secretagogue, the cleaner ipamorelin avoids GHRP-6’s cortisol and appetite footprint, though it too lacks the outcome evidence to justify the broader claims; tested product is essential either way.

Inexpensive, as a decades-old, simple peptide that is cheap to synthesize. The low cost reflects an unapproved research chemical rather than a validated therapy, and gray-market product carries no quality guarantee.

Synthesized overseas, predominantly in China, and sold as research material with limited quality assurance, where a certificate of analysis is the only check.

China and research vendorsThe dominant source of GHRP-6, sold cheaply as research-use-only material.Established classAs a decades-old, simple hexapeptide, it is widely and inexpensively synthesized.Clinic and stack channelBodybuilding and anti-aging clinics distribute it, frequently combined with GHRH analogs.

At a glance

Generation
First GH secretagogue
Side effect
Strong hunger
Mechanism
Ghrelin receptor
Status
Largely superseded

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about GHRP-6.

Nothing outstanding on this one.

Sources

The studies that matter

  • Bowers, Endocrinology1984

    First showed GHRP-6 releases growth hormone dose-dependently across species including humans, founding the GH-secretagogue field.

  • Ghrelin discovery1990s

    GHRP-6 served as the key tool that led to identifying the ghrelin receptor and then the hormone ghrelin itself.

  • Secretagogue characterization1980s-1990s

    Established that it releases GH by a mechanism distinct from GHRH, and characterized its appetite, gastric-motility, cortisol and prolactin effects.

  • Ipamorelin comparison1998

    Ipamorelin was introduced as the first selective GH secretagogue, defined explicitly against GHRP-6’s broader hormonal footprint.

  • Outcome trialsnone

    Despite proven GH release, there are no outcome trials showing GHRP-6 improves body composition, recovery or longevity in humans.